Borago Officinalis Flower

Dosage for Borago Officinalis Flower allergenic extract is highly individualized and must be determined by an allergist or immunologist based on the patient's sensitivity levels. There is no 'one-size-fits-all' dose.

• Diagnostic Testing: For skin prick testing, a single drop of the extract (typically at a concentration of 1:10 or 1:20 w/v) is applied to the skin. For intradermal testing, 0.02 mL of a much more dilute concentration (e.g., 1:1000 or 1:10,000 w/v) is injected.
• Immunotherapy (Build-up Phase): Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:100,000 dilution). Doses are increased weekly or bi-weekly by 50% to 100% until the maintenance dose is reached.
• Maintenance Phase: Once the maintenance dose is achieved (typically 0.5 mL of a 1:10 or 1:20 concentration), the interval between injections is increased to every 2 to 4 weeks.

Borago Officinalis Flower extracts may be used in children, but extreme caution is required. Dosing is generally similar to adult dosing but must be adjusted based on the child's weight, age, and severity of allergic symptoms. Clinical studies have shown that immunotherapy is generally effective in children as young as 5 years old, but the decision to start treatment in younger children must be made on a case-by-case basis by a pediatric allergist.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared through the kidneys in a manner that would lead to systemic toxicity. However, the patient's overall health must be considered before starting immunotherapy.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment. However, if the patient is taking oral borage supplements (which contain pyrrolizidine alkaloids), hepatic function must be monitored closely, as these can be hepatotoxic.

Elderly Patients

Elderly patients (over 65) should be evaluated for cardiovascular stability before receiving Borago Officinalis Flower extract. The risk of systemic reactions, including anaphylaxis, may be more difficult to manage in patients with underlying heart disease or those taking beta-blockers.

Borago Officinalis Flower allergenic extract is never for self-administration. It must be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.

1. 1Preparation: The clinician will inspect the vial for particulate matter or discoloration. The extract is drawn into a specialized allergy syringe.
2. 2Administration: For immunotherapy, the injection is given subcutaneously, usually in the posterior aspect of the upper arm.
3. 3Observation: Patients must remain in the clinic for at least 30 minutes following the injection to monitor for signs of a systemic reaction.
4. 4Storage: Vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed. If more than 2-4 weeks have passed since the last scheduled injection, the allergist will typically drop the dose back several levels to prevent a systemic reaction upon re-exposure.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level. Signs include:

• Severe local swelling at the injection site
• Generalized hives (urticaria)
• Wheezing or difficulty breathing
• Hypotension (low blood pressure)

In the event of an overdose, emergency protocols for anaphylaxis, including the administration of epinephrine, must be initiated immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to administer this medication yourself without medical guidance.

Most patients receiving Borago Officinalis Flower extract will experience some form of local reaction. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A red patch at the site of injection or skin test. This usually appears within minutes and resolves within a few hours.
• Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is smaller than the size of a half-dollar, it is considered a normal local reaction.
• Itching (Pruritus): Intense itching at the site of administration is very common and is a direct result of histamine release.

• Large Local Reactions: Swelling that extends beyond the immediate injection site, sometimes involving the entire upper arm. This may require the application of ice packs or the use of oral antihistamines.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy injection.
• Mild Nasal Congestion: A slight increase in hay fever-like symptoms shortly after treatment.

• Systemic Urticaria: Hives appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Gastrointestinal Distress: Nausea or abdominal cramping, which can be an early sign of a systemic allergic response.

> Warning: Stop taking Borago Officinalis Flower and call your doctor immediately if you experience any of these symptoms, which may indicate anaphylaxis.

• Difficulty Breathing: Wheezing, chest tightness, or a feeling of 'throat closing.'
• Hypotension: Dizziness, lightheadedness, or fainting caused by a sudden drop in blood pressure.
• Tachycardia: A rapid or irregular heartbeat.
• Cyanosis: A bluish tint to the lips or fingernails, indicating poor oxygenation.
• Seizures: Though extremely rare, severe systemic reactions can lead to neurological symptoms.

When used as an allergenic extract, there are few documented long-term side effects. However, if the Borago Officinalis Flower is consumed orally (as a supplement) over long periods, there is a risk of Hepatotoxicity. Borage contains pyrrolizidine alkaloids (PAs) such as lycopsamine. Chronic exposure to PAs can lead to hepatic veno-occlusive disease (HVOD), a condition where the small veins in the liver become blocked, leading to cirrhosis and liver failure. Standardized pharmaceutical extracts for injection are typically processed to minimize these risks, but patients should be aware of this potential if using non-pharmaceutical borage products.

Most allergenic extracts, including those derived from Borago Officinalis Flower, carry a class-wide warning regarding the risk of severe systemic reactions.

Summary of Warning: This product can cause severe life-threatening systemic reactions, including anaphylaxis. It must only be administered by healthcare providers who are experienced in the use of allergenic extracts and are prepared to manage such reactions. Patients with unstable asthma or those taking beta-blockers may be at increased risk of fatal outcomes if a reaction occurs.

Report any unusual symptoms to your healthcare provider immediately. Early intervention is key to managing side effects effectively.

Borago Officinalis Flower extract is a potent biological agent. Its use is restricted to diagnostic and therapeutic procedures under strict medical supervision. Patients must be informed that the very substance used to treat their allergy can, in itself, trigger a severe allergic reaction.

No specific FDA black box warning exists solely for 'Borago Officinalis Flower,' but it falls under the general black box warning for Allergenic Extracts. This warning emphasizes that these products can cause anaphylaxis and should only be used in settings where emergency resuscitative equipment and personnel are immediately available. Patients must be observed for at least 30 minutes post-injection.

• Anaphylaxis Risk: The primary risk is a systemic allergic reaction. Risk factors include a high level of sensitivity, a large dose, or a rapid increase in dose during the build-up phase.
• Asthma Stability: Patients with poorly controlled or unstable asthma are at a significantly higher risk for a severe or fatal reaction to Borago Officinalis Flower injections. Asthma must be well-controlled before an injection is administered.
• Hepatotoxicity: For any form of Borago Officinalis Flower that is ingested, the presence of pyrrolizidine alkaloids (PAs) poses a risk of liver damage. Patients with pre-existing liver disease should avoid all borage products unless specifically directed by a hepatologist.
• Cardiovascular Disease: Patients with significant heart disease may not be able to tolerate the physiological stress of a systemic reaction or the effects of epinephrine if it must be administered.

• Peak Flow Meter: Patients with asthma should have their peak expiratory flow (PEF) measured before each injection.
• Vital Signs: Blood pressure and heart rate should be monitored if a patient feels unwell after administration.
• Liver Function Tests (LFTs): If a patient is using borage-derived products orally, regular monitoring of ALT, AST, and bilirubin is recommended to screen for PA-induced hepatotoxicity.

Most patients can drive after receiving a Borago Officinalis Flower injection, provided they have completed the 30-minute observation period and feel fine. However, if a systemic reaction occurs or if the patient is given antihistamines (which cause drowsiness) to treat a local reaction, they should not drive or operate machinery.

Alcohol should be avoided on the day of an immunotherapy injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of absorption of the allergen and potentially increase the risk or severity of a systemic reaction.

Immunotherapy with Borago Officinalis Flower is typically a long-term commitment (3 to 5 years). Stopping treatment prematurely will likely result in the return of allergic symptoms. There is no 'withdrawal' syndrome, but the immunological benefits will gradually fade.

> Important: Discuss all your medical conditions with your healthcare provider before starting Borago Officinalis Flower.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are contraindicated in many patients receiving allergenic extracts. Beta-blockers can make a systemic reaction (anaphylaxis) more severe and, more importantly, they can make the reaction resistant to the effects of epinephrine (adrenaline). If a patient on a beta-blocker experiences anaphylaxis, the standard rescue treatment may fail.

• ACE Inhibitors (e.g., Lisinopril): Some evidence suggests that patients taking ACE inhibitors may be at an increased risk for more severe systemic reactions to allergenic extracts or insect stings. The mechanism is thought to involve the inhibition of bradykinin breakdown.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, which might be used to treat a reaction, leading to a hypertensive crisis.

• Antihistamines: While often used to treat side effects, taking antihistamines before a diagnostic skin test will result in a false-negative result. Antihistamines must be discontinued for 3 to 7 days before skin testing.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can interfere with the body's response to epinephrine.

• Alcohol: As mentioned, alcohol increases vasodilation and can exacerbate an allergic response. It should be avoided for 24 hours around the time of injection.
• High-Fat Meals: While not directly interacting with the extract, heavy meals can sometimes mask the early gastrointestinal symptoms of a systemic reaction.

• St. John's Wort: May induce enzymes that theoretically could affect the metabolism of other medications used to treat allergic reactions, though the clinical significance is low.
• Other PA-containing Herbs (e.g., Comfrey): Using other herbs that contain pyrrolizidine alkaloids alongside borage increases the cumulative risk of liver toxicity. This is a pharmacodynamic interaction where the toxic effects are additive.

• Skin Tests: Borago Officinalis Flower extract is itself used for testing. However, the use of topical steroids at the test site can suppress the reaction, leading to inaccurate results.
• Total IgE: Immunotherapy may cause a transient rise in total IgE levels before they eventually decline.

For each major interaction, the primary management strategy is avoidance or careful timing. If a patient must remain on a beta-blocker, the healthcare provider must weigh the risks of immunotherapy against the risks of the allergic condition itself.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients whose asthma is not stabilized with medication are at an extremely high risk of fatal bronchospasm if they have a systemic reaction to Borago Officinalis Flower extract.
• Recent Myocardial Infarction (Heart Attack): The cardiovascular strain of a potential anaphylactic reaction makes immunotherapy too risky in the immediate post-MI period (usually within 3-6 months).
• Hypersensitivity to Diluents: If a patient is known to be allergic to components of the extract's carrier solution, such as phenol or human serum albumin, the extract must not be used.
• Active Hepatic Disease: Due to the potential for pyrrolizidine alkaloid toxicity in borage products, patients with active hepatitis or cirrhosis should not use borage-derived substances.

• Beta-Blocker Therapy: As discussed, this makes managing anaphylaxis difficult. It is a relative contraindication depending on the necessity of the beta-blocker and the severity of the allergy.
• Pregnancy: While not a reason to stop immunotherapy that is already at a maintenance level, it is generally recommended not to start a new course of Borago Officinalis Flower immunotherapy during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may have unpredictable immune responses to allergenic extracts.

Patients allergic to Borago Officinalis Flower may also show sensitivity to other members of the Boraginaceae family, such as Comfrey (Symphytum officinale) or Forget-me-not (Myosotis). There is also a known cross-reactivity between certain plant pollens and foods (Pollen-Food Allergy Syndrome). Patients sensitive to borage may occasionally experience oral itching when eating related botanical products.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Borago Officinalis Flower.

Borago Officinalis Flower extract is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not direct teratogenicity (birth defects) from the extract itself, but the danger that a systemic reaction (anaphylaxis) poses to the fetus. Anaphylaxis in the mother can lead to a sudden drop in blood pressure and uterine contraction, resulting in fetal hypoxia (lack of oxygen) or miscarriage. Therefore, initiating immunotherapy during pregnancy is usually avoided. If a patient is already on a stable maintenance dose and is tolerating it well, the clinician may choose to continue the treatment at that same dose or a reduced dose.

It is not known whether the allergenic proteins or pyrrolizidine alkaloids from Borago Officinalis Flower pass into human breast milk. Because the proteins are likely digested in the infant's gut, the risk from immunotherapy is considered low. However, if the mother is consuming borage oil or flower tea, PAs can pass into the milk and pose a risk of liver damage to the nursing infant. Caution is advised, and breastfeeding mothers should consult their pediatrician.

Allergen immunotherapy with Borago Officinalis Flower is generally considered safe and effective for children aged 5 and older. It can be particularly beneficial in preventing the 'allergic march' (the progression from allergic rhinitis to asthma). However, younger children may have difficulty communicating the early symptoms of a systemic reaction, making the 30-minute observation period even more critical. Dosing must be meticulously managed by a specialist.

Patients over the age of 65 may have a higher prevalence of cardiovascular and pulmonary comorbidities. This makes them more vulnerable to the complications of anaphylaxis. Additionally, elderly patients are more likely to be taking multiple medications (polypharmacy) that could interact with the extract or its emergency treatments. A thorough risk-benefit analysis is required for older adults.

There is no evidence that renal impairment significantly alters the response to Borago Officinalis Flower allergenic extracts. However, patients with end-stage renal disease (ESRD) may have altered immune function, which could theoretically impact the efficacy of immunotherapy.

Patients with hepatic impairment (Child-Pugh Class B or C) should avoid borage products. While the injectable extract is processed, the historical association of Borago officinalis with hepatotoxic pyrrolizidine alkaloids makes it a high-risk substance for those with compromised liver function. Any signs of jaundice or increased liver enzymes should lead to immediate discontinuation.

> Important: Special populations require individualized medical assessment to ensure safety and efficacy.

Borago Officinalis Flower extract functions through a dual immunological mechanism. For diagnostic purposes, it acts as an antigen that binds to allergen-specific IgE antibodies on the surface of mast cells. This triggers the release of pre-formed mediators like histamine, which causes local vasodilation and edema (the wheal and flare).

For therapeutic purposes (immunotherapy), the extract induces a state of 'desensitization' and eventually 'tolerance.' This involves the expansion of regulatory T-cells (Tregs) that secrete IL-10 and TGF-beta, cytokines that suppress the allergic Th2 response. It also promotes a 'class switch' in B-cells from producing IgE to producing IgG4. IgG4 acts as a blocking antibody, preventing the allergen from reaching the IgE on mast cells.

• Onset of Action: For skin testing, the onset is rapid (15-20 minutes). For immunotherapy, the clinical benefit usually takes 3 to 6 months to become apparent.
• Duration of Effect: A single skin test reaction lasts 2-4 hours. The effects of a completed 3-5 year course of immunotherapy can last for several years or even decades.
• Tolerance: Unlike many drugs, 'tolerance' here is the desired therapeutic goal—the immune system becoming non-reactive to the allergen.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | High (to IgE/IgG antibodies) |

| Half-life | Minutes (Proteins); Years (Immune Memory) |

| Tmax | 15-30 minutes (Local absorption) |

| Metabolism | Proteolysis (Tissue/Plasma) |

| Excretion | Renal (Peptide fragments) |

• Molecular Formula: Complex mixture of proteins, glycoproteins, and polysaccharides.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for major allergens.
• Solubility: Soluble in aqueous solutions and saline.
• Structure: The extract contains various proteins, including those from the Bet v 1-like family and profilins, which are common plant allergens.

Borago Officinalis Flower is classified as a Non-Standardized Plant Allergenic Extract. It belongs to the broader category of Allergenic Extracts [EPC]. Related medications include extracts of Ragweed, Timothy Grass, and various tree pollens used in the diagnosis and treatment of respiratory allergies.